Mgr. Adriana Ladungová
Research specialist - PhD student, Michal Šmída Research Group
office: bldg. E35/142
Kamenice 753/5
625 00 Brno
phone: | +420 549 49 5875 |
---|---|
e‑mail: |
Total number of publications: 20
2022
-
Prediction of novel treatment options for venetoclax-resistant AML cells based on drug repurposing.
Year: 2022, type: Conference abstract
2021
-
CD19 promoter hypermethylation as means of antigen-negative escape to CART-19 therapy.
Year: 2021, type: Conference abstract
-
Drug repositioning in genetically defined CLL cases reveals a potentional novel therapeutic use for approved drugs.
Year: 2021, type: Conference abstract
-
Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro
Journal for ImmunoTherapy of Cancer, year: 2021, volume: 9, edition: 8, DOI
-
In vivo antigen-negative escape to CART-19 caused by CD19 promotor hypermethylation.
Year: 2021, type: Conference abstract
2020
-
CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells
Plos one, year: 2020, volume: 15, edition: 3, DOI
-
CRISPR/CAS9 technology: a useful tool in the study of chronic lymphocytic leukemia
Year: 2020, type: Conference abstract
-
Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia
Journal for ImmunoTherapy of Cancer, year: 2020, volume: 8, edition: 1, DOI
-
The use of CRISPR/Cas9 technology in the study of chronic lymphocytic leukemia.
Year: 2020, type: Conference abstract
2019
-
Tour through the drug screening in the lab of Functional Genomics
Year: 2019, type: Conference abstract